Skip to main content
Top
Published in: Clinical Rheumatology 5/2011

01-05-2011 | Brief Report

Takayasu’s arteritis progression on anti-TNF biologics: a case series

Authors: Mohammed Osman, Stephen Aaron, Michelle Noga, Elaine Yacyshyn

Published in: Clinical Rheumatology | Issue 5/2011

Login to get access

Abstract

Takayasu’s arteritis (TA) is a rare granulomatous vasculitic disease that affects the aorta and its major branches. Recent studies have suggested that anti-TNFα biological therapies are highly effective in treating TA refractory to conventional immunosuppressive therapy. We describe two patients with TA: one with progressive TA despite management with two different anti-TNFα agents, infliximab and adalimumab, and another who developed TA while treated with infliximab for the management of pre-existing Crohn’s disease. From our observations, we believe that a multicentered randomized study should be designed to assess the extent of resistance to these agents when different therapeutic doses are employed for managing TA.
Literature
1.
go back to reference Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369(9573):1641–5167PubMedCrossRef Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369(9573):1641–5167PubMedCrossRef
2.
go back to reference Reny JL et al (2003) Association of Takayasu’s arteritis and Crohn’s disease: results of a study on 44 Takayasu patients and review of the literature. Ann Med Interne (Paris) 154(2):85–90 Reny JL et al (2003) Association of Takayasu’s arteritis and Crohn’s disease: results of a study on 44 Takayasu patients and review of the literature. Ann Med Interne (Paris) 154(2):85–90
3.
go back to reference Chung SA, Seo P (2009) Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 21(1):3–9PubMedCrossRef Chung SA, Seo P (2009) Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 21(1):3–9PubMedCrossRef
4.
go back to reference Maffei S et al (2009) Refractory Takayasu arteritis successfully treated with infliximab. Eur Rev Med Pharmacol Sci 13(1):63–65PubMed Maffei S et al (2009) Refractory Takayasu arteritis successfully treated with infliximab. Eur Rev Med Pharmacol Sci 13(1):63–65PubMed
5.
go back to reference Molloy ES et al (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67(11):1567–1569PubMedCrossRef Molloy ES et al (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67(11):1567–1569PubMedCrossRef
6.
go back to reference Filocamo G et al (2008) Treatment of Takayasu’s arteritis with tumor necrosis factor antagonists. J Pediatr 153(3):432–434PubMedCrossRef Filocamo G et al (2008) Treatment of Takayasu’s arteritis with tumor necrosis factor antagonists. J Pediatr 153(3):432–434PubMedCrossRef
7.
go back to reference Wolbink GJ et al (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64(5):704–707PubMedCrossRef Wolbink GJ et al (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64(5):704–707PubMedCrossRef
8.
go back to reference St Clair EW et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(6):1451–1459PubMedCrossRef St Clair EW et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(6):1451–1459PubMedCrossRef
9.
go back to reference Wolbink GJ et al (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711–715PubMedCrossRef Wolbink GJ et al (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711–715PubMedCrossRef
10.
go back to reference Baert F et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348(7):601–608PubMedCrossRef Baert F et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348(7):601–608PubMedCrossRef
11.
go back to reference Bartelds GM et al (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis 69(5):817–821PubMedCrossRef Bartelds GM et al (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis 69(5):817–821PubMedCrossRef
12.
go back to reference El-Matary W, Persad R (2009) Takayasu’s aortitis and infliximab. J Pediatr 155(1):151PubMed El-Matary W, Persad R (2009) Takayasu’s aortitis and infliximab. J Pediatr 155(1):151PubMed
13.
go back to reference Farrant M et al (2008) Takayasu’s arteritis following Crohn’s disease in a young woman: any evidence for a common pathogenesis? World J Gastroenterol 14(25):4087–4090PubMedCrossRef Farrant M et al (2008) Takayasu’s arteritis following Crohn’s disease in a young woman: any evidence for a common pathogenesis? World J Gastroenterol 14(25):4087–4090PubMedCrossRef
14.
go back to reference Levitsky J, Harrison JR, Cohen RD (2002) Crohn’s disease and Takayasu’s arteritis. J Clin Gastroenterol 34(4):454–456PubMedCrossRef Levitsky J, Harrison JR, Cohen RD (2002) Crohn’s disease and Takayasu’s arteritis. J Clin Gastroenterol 34(4):454–456PubMedCrossRef
15.
go back to reference Owyang C et al (1979) Takayasu’s arteritis in Crohn’s disease. Gastroenterology 76(4):825–828PubMed Owyang C et al (1979) Takayasu’s arteritis in Crohn’s disease. Gastroenterology 76(4):825–828PubMed
16.
go back to reference Friedman CJ, Tegtmeyer CJ (1979) Crohn’s disease associated with Takayasu’s arteritis. Dig Dis Sci 24(12):954–958PubMedCrossRef Friedman CJ, Tegtmeyer CJ (1979) Crohn’s disease associated with Takayasu’s arteritis. Dig Dis Sci 24(12):954–958PubMedCrossRef
17.
go back to reference Johnston SL, Lock RJ, Gompels MM (2002) Takayasu arteritis: a review. J Clin Pathol 55(7):481–486PubMed Johnston SL, Lock RJ, Gompels MM (2002) Takayasu arteritis: a review. J Clin Pathol 55(7):481–486PubMed
18.
go back to reference Karlinger K et al (2000) The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 35(3):154–167PubMedCrossRef Karlinger K et al (2000) The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 35(3):154–167PubMedCrossRef
Metadata
Title
Takayasu’s arteritis progression on anti-TNF biologics: a case series
Authors
Mohammed Osman
Stephen Aaron
Michelle Noga
Elaine Yacyshyn
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1658-1

Other articles of this Issue 5/2011

Clinical Rheumatology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.